iRadimed Analyst Price Targets - Benzinga

iRadimed Corp

IRMDNASDAQ

Trade with Public

Trade with Public

$88.24

0.590.67%

Últ. Act.: Oct 20, 4:00 PM

$88.24

0.590.67%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

iRadimed Analyst Price Targets - Benzinga

iRadimed Analyst Price Targets

Wall Street analyst price targets and consensus rating for iRadimed (IRMD).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

2Buy

1Hold

Consensus RatingBuy# Analysts3Avg. Consensus PT$94Upside to Avg. PT+6.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	Needham	David Saxon	Initiate	Hold	—
Apr 2, 2026	Freedom Broker	Ilya Zubkov	Initiate	Buy	$116
Feb 14, 2025	Roth MKM	Jason Wittes	PT Raise	Buy	$60→$72
Aug 2, 2024	Roth MKM	Jason Wittes	PT Cut	Buy	$65→$60
Apr 22, 2024	Roth MKM	Jason Wittes	Reinstates	Buy	$65

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Initiates Coverage On iRadimed with Hold Rating

Needham analyst David Saxon initiates coverage on iRadimed (NASDAQ:IRMD) with a Hold rating.

Benzinga Newsdesk

PRO
Roth MKM Reiterates Buy on iRadimed, Raises Price Target to $72

Roth MKM analyst Jason Wittes reiterates iRadimed (NASDAQ:IRMD) with a Buy and raises the price target from $60 to $72.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on iRadimed, Lowers Price Target to $60

Roth MKM analyst Jason Wittes maintains iRadimed (NASDAQ:IRMD) with a Buy and lowers the price target from $65 to $60.

Benzinga Newsdesk

PRO
Roth MKM Reinstates Buy on iRadimed, Announces $65 Price Target

Roth MKM analyst Jason Wittes reinstates iRadimed (NASDAQ:IRMD) with a Buy and announces $65 price target.

Benzinga Newsdesk

PRO
UPDATE: Roth On iRadimed Price Target Raise: Firm Highlights Strong Monitor Sales Offsetting Pump Sales With Co. On Track For All-Time Revenue Highs; Expects Next-Gen Pump To Be Approved Late 2021 To Early 2022 Which Could Further Surge Revenues

Benzinga Newsdesk

PRO
Roth Capital Maintains Buy on iRadimed, Raises Price Target to $36

Roth Capital analyst Scott Henry maintains iRadimed (NASDAQ:IRMD) with a Buy and raises the price target from $32 to $36.

Benzinga Newsdesk